Hidekazu Inoue

USPTO Granted Patents = 13 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 34(Granted Patents)

Location History:

Ibaraki, JP (2000)
Takatsuki, JP (2001 - 2003)
Osaka, JP (2001 - 2014)
Tokyo, JP (2016)
Ota-ku, JP (2020 - 2021)

Company Filing History:

Daiichi Sankyo Company, Limited

patents

2 out of 19

Asubio Pharma Co. Ltd.

patents

4. 1 out of 1

Ausbio Pharma Co., Ltd.

patent

Years Active: 2000-2021

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11034659 - Pyrimidine derivative (2021-06-15),

2. 10774087 - Sulfonamide derivative having coumarin skeleton (2020-09-15),

3. 9464076 - Benzothiophene derivative (2016-10-11),

4. 8901315 - Thienopyrazole derivative having PDE7 inhibitory activity (2014-12-02),

5. 7943624 - Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors (2011-05-17),

6. 7932250 - Thienopyrazole derivative having PDE7 inhibitory activity (2011-04-26),

7. 7713972 - Imidazotriazinone derivatives as PDE 7 (phosphodiesterase 7) inhibitors (2010-05-11),

8. 7268128 - 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action (2007-09-11),

9. 6541480 - 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor (2003-04-01),

10. 6331548 - 1-cycloalkyl-1,8-naphthyridin-4-one derivative as type IV phosphodiesterase inhibitor (2001-12-18),

11. 6297248 - 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor (2001-10-02),

12. 6051569 - 1'S, 5R, 6R-carbapenem derivatives and antimicrobial agents comprising (2000-04-18),

13. 6049009 - Production method of optically active trans-vinylsulfide alcohol (2000-04-11),

Title: Innovations of Hidekazu Inoue

Introduction

Hidekazu Inoue is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating cystic fibrosis and diseases associated with MTHFD2 overexpression. With a total of 13 patents to his name, Inoue's work reflects a commitment to advancing medical science.

Latest Patents

Inoue's latest patents include a pyrimidine derivative aimed at treating cystic fibrosis. This invention focuses on providing compounds that open chloride channels independent of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The compounds are designed to activate calcium-dependent chloride channels (CaCCs) through G-protein coupled receptor 39 (GPR39) agonism, promoting chloride ion secretion. Another notable patent involves a sulfonamide derivative with a coumarin skeleton, which inhibits MTHFD2 and is useful for treating diseases caused by its overexpression.

Career Highlights

Throughout his career, Inoue has worked with notable companies such as Suntory Limited and Daiichi Sankyo Company, Limited. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and research.

Collaborations

Inoue has collaborated with esteemed colleagues, including Yasuhiro Hayashi and Hidenobu Murafuji. These partnerships have facilitated the development of groundbreaking inventions in the pharmaceutical sector.

Conclusion

Hidekazu Inoue's contributions to medical science through his innovative patents demonstrate his dedication to improving health outcomes. His work continues to influence the field of pharmaceuticals, showcasing the importance of research and collaboration in driving advancements.

This text is generated by artificial intelligence and may not be accurate.